MIT News - Artificial intelligence 09月25日 18:02
MIT新框架优化治疗组合实验
index_new5.html
../../../zaker_core/zaker_tpl_static/wap/tpl_guoji1.html

 

MIT研究人员开发了一种新的理论框架,用于研究治疗交互机制。该框架允许科学家高效估计治疗组合如何影响一组单元(如细胞),从而通过更少的昂贵实验收集更准确的数据。例如,研究相互关联的基因如何影响癌细胞生长的生物学家可能需要同时靶向多个基因。由于每轮实验可能有数十亿种潜在组合,选择测试的子集可能使实验数据产生偏差。新框架通过并行分配所有治疗并调整每种治疗的速率来设计无偏实验。研究人员理论上证明了这个框架中的近似最优策略,并通过多轮实验的模拟验证了其最小化误差率。该技术可能有助于科学家更好地理解疾病机制,开发治疗癌症或遗传性疾病的新药物。

🔬该框架通过并行分配所有治疗并调整每种治疗的速率来设计无偏实验,从而高效估计治疗组合如何影响一组单元(如细胞),帮助科学家通过更少的昂贵实验收集更准确的数据。

🧬在研究相互关联的基因如何影响癌细胞生长时,生物学家可能需要同时靶向多个基因。新框架通过减少实验偏差,使得选择测试的子集不再关键,从而优化实验设计。

⚙️研究人员理论上证明了这个框架中的近似最优策略,并通过多轮实验的模拟验证了其最小化误差率。该技术可能有助于科学家更好地理解疾病机制,开发治疗癌症或遗传性疾病的新药物。

🔄实验过程中,用户收集结果并反馈到框架中,框架输出理想剂量策略,主动适应多轮实验策略,从而优化实验设计并减少误差。

🔹该框架通过将剂量水平设定为概率,使每个细胞随机接收治疗组合,从而减少实验偏差。高剂量水平使更多细胞接收该治疗,低剂量水平则使较少细胞接收。

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their approach allows scientists to efficiently estimate how combinations of treatments will affect a group of units, such as cells, enabling a researcher to perform fewer costly experiments while gathering more accurate data.

As an example, to study how interconnected genes affect cancer cell growth, a biologist might need to use a combination of treatments to target multiple genes at once. But because there could be billions of potential combinations for each round of the experiment, choosing a subset of combinations to test might bias the data their experiment generates. 

In contrast, the new framework considers the scenario where the user can efficiently design an unbiased experiment by assigning all treatments in parallel, and can control the outcome by adjusting the rate of each treatment.

The MIT researchers theoretically proved a near-optimal strategy in this framework and performed a series of simulations to test it in a multiround experiment. Their method minimized the error rate in each instance.

This technique could someday help scientists better understand disease mechanisms and develop new medicines to treat cancer or genetic disorders.

“We’ve introduced a concept people can think more about as they study the optimal way to select combinatorial treatments at each round of an experiment. Our hope is this can someday be used to solve biologically relevant questions,” says graduate student Jiaqi Zhang, an Eric and Wendy Schmidt Center Fellow and co-lead author of a paper on this experimental design framework.

She is joined on the paper by co-lead author Divya Shyamal, an MIT undergraduate; and senior author Caroline Uhler, the Andrew and Erna Viterbi Professor of Engineering in EECS and the MIT Institute for Data, Systems, and Society (IDSS), who is also director of the Eric and Wendy Schmidt Center and a researcher at MIT’s Laboratory for Information and Decision Systems (LIDS). The research was recently presented at the International Conference on Machine Learning.

Simultaneous treatments

Treatments can interact with each other in complex ways. For instance, a scientist trying to determine whether a certain gene contributes to a particular disease symptom may have to target several genes simultaneously to study the effects.

To do this, scientists use what are known as combinatorial perturbations, where they apply multiple treatments at once to the same group of cells.

“Combinatorial perturbations will give you a high-level network of how different genes interact, which provides an understanding of how a cell functions,” Zhang explains.

Since genetic experiments are costly and time-consuming, the scientist aims to select the best subset of treatment combinations to test, which is a steep challenge due to the huge number of possibilities.

Picking a suboptimal subset can generate biased results by focusing only on combinations the user selected in advance.

The MIT researchers approached this problem differently by looking at a probabilistic framework. Instead of focusing on a selected subset, each unit randomly takes up combinations of treatments based on user-specified dosage levels for each treatment.

The user sets dosage levels based on the goal of their experiment — perhaps this scientist wants to study the effects of four different drugs on cell growth. The probabilistic approach generates less biased data because it does not restrict the experiment to a predetermined subset of treatments.

The dosage levels are like probabilities, and each cell receives a random combination of treatments. If the user sets a high dosage, it is more likely most of the cells will take up that treatment. A smaller subset of cells will take up that treatment if the dosage is low.

“From there, the question is how do we design the dosages so that we can estimate the outcomes as accurately as possible? This is where our theory comes in,” Shyamal adds.

Their theoretical framework shows the best way to design these dosages so one can learn the most about the characteristic or trait they are studying.

After each round of the experiment, the user collects the results and feeds those back into the experimental framework. It will output the ideal dosage strategy for the next round, and so on, actively adapting the strategy over multiple rounds.

Optimizing dosages, minimizing error

The researchers proved their theoretical approach generates optimal dosages, even when the dosage levels are affected by a limited supply of treatments or when noise in the experimental outcomes varies at each round.

In simulations, this new approach had the lowest error rate when comparing estimated and actual outcomes of multiround experiments, outperforming two baseline methods.

In the future, the researchers want to enhance their experimental framework to consider interference between units and the fact that certain treatments can lead to selection bias. They would also like to apply this technique in a real experimental setting.

“This is a new approach to a very interesting problem that is hard to solve. Now, with this new framework in hand, we can think more about the best way to design experiments for many different applications,” Zhang says.

This research is funded, in part, by the Advanced Undergraduate Research Opportunities Program at MIT, Apple, the National Institutes of Health, the Office of Naval Research, the Department of Energy, the Eric and Wendy Schmidt Center at the Broad Institute, and a Simons Investigator Award.

Fish AI Reader

Fish AI Reader

AI辅助创作,多种专业模板,深度分析,高质量内容生成。从观点提取到深度思考,FishAI为您提供全方位的创作支持。新版本引入自定义参数,让您的创作更加个性化和精准。

FishAI

FishAI

鱼阅,AI 时代的下一个智能信息助手,助你摆脱信息焦虑

联系邮箱 441953276@qq.com

相关标签

MIT 治疗组合 实验设计 理论框架 基因研究 癌症治疗 遗传性疾病
相关文章